Paper16683074
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W and 12 others. Invest New Drugs, 2006. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Papers, record 16683074. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16683074
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cisplatin | Major topic |
| Neoplasms | Major topic |
| Sesquiterpenes | Major topic |
| Adult | |
| Aged | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Infusions, Intravenous | |
| Male | |
| Maximum Tolerated Dose | |
| Middle Aged | |
| Neoplasm Staging |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14532976 | Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. | Int J Oncol | 2003 | https://conductscience.org/library/papers/14532976 | PubMed |
| 2 | 15685033 | Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. | Am J Clin Oncol | 2005 | https://conductscience.org/library/papers/15685033 | PubMed |
| 3 | 10458260 | Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10458260 | PubMed |
| 4 | 10831281 | Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. | Anticancer Drugs | 2000 | https://conductscience.org/library/papers/10831281 | PubMed |
| 5 | 1591066 | Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. | Eur J Cancer | 1992 | https://conductscience.org/library/papers/1591066 | PubMed |
| 6 | 856436 | Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. | Cancer | 1977 | https://conductscience.org/library/papers/856436 | PubMed |
| 7 | 10423161 | Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). | Biochem Pharmacol | 1999 | https://conductscience.org/library/papers/10423161 | PubMed |
| 8 | 11118470 | Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. | J Clin Oncol | 2000 | https://conductscience.org/library/papers/11118470 | PubMed |
| 9 | 10521061 | Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. | Am J Clin Oncol | 1999 | https://conductscience.org/library/papers/10521061 | PubMed |
| 10 | 1244564 | Prediction of creatinine clearance from serum creatinine. | Nephron | 1976 | https://conductscience.org/library/papers/1244564 | PubMed |
| 11 | 10736422 | Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). | Biochem Pharmacol | 2000 | https://conductscience.org/library/papers/10736422 | PubMed |
| 12 | 10655437 | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/10655437 | PubMed |
| 13 | 9000568 | Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. | Cancer Res | 1997 | https://conductscience.org/library/papers/9000568 | PubMed |
| 14 | 9797706 | Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. | Eur J Cancer | 1998 | https://conductscience.org/library/papers/9797706 | PubMed |
| 15 | 2402017 | Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. | J Natl Cancer Inst | 1990 | https://conductscience.org/library/papers/2402017 | PubMed |
| 16 | 12566077 | Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. | Biochem Pharmacol | 2003 | https://conductscience.org/library/papers/12566077 | PubMed |
| 17 | 498155 | Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/498155 | PubMed |
| 18 | 9416969 | Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). | Biochem Pharmacol | 1997 | https://conductscience.org/library/papers/9416969 | PubMed |
| 19 | 15161692 | Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15161692 | PubMed |
| 20 | 15642808 | Cone damage in patients receiving high-dose irofulven treatment. | Arch Ophthalmol | 2005 | https://conductscience.org/library/papers/15642808 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37996508 | Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. | Sci Rep | 2023 | https://conductscience.org/library/papers/37996508 | PubMed |
| 19938810 | Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven. | J Org Chem | 2009 | https://conductscience.org/library/papers/19938810 | PubMed |
| 18227973 | Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. | Invest New Drugs | 2008 | https://conductscience.org/library/papers/18227973 | PubMed |
| 17628744 | A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. | Invest New Drugs | 2007 | https://conductscience.org/library/papers/17628744 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NPEPPS | 9520 | PubTator's text mining | https://conductscience.org/library/genes/9520 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16683074
GET https://conductscience.org/api/papers/v1/16683074/references?page=2